Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 11, 2010, Pages 4973-4978

  Puig Domingo, Manel ^a,d   Resmini, Eugenia ^b   Gomez Anson, Beatriz ^b   Nicolau, Joana ^a   Mora, Mireia ^a   Palomera, Elisabet ^c   Martí, Camelia ^b   Halperin, Irene ^a   Webb, Susan M ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE MATARÓ   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HYPOPHYSIS TUMOR; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

EID: 78049511231     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0573     Document Type: Article

References (26)

1. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89:1613-1617
2. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 91:1239-1245
3. Katznelson L 2008 An update on treatment strategies for acromegaly. Expert Opin Pharmacother 9:2273-2280
4. Bronstein MD 2006 Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res 35:129-134
5. Ballarè E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A 2001 Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86:3809-3814
6. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D 2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 92:1592-1599
7. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD 2006 Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29:826-830
8. Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T 2003 Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228:533-538
9. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465-4473
10. McKeage K, Cheer S, Wagstaff AJ 2003 Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 63:2473-2499
11. Jallad RS, Musolino NR, Salgado LR, Bronstein MD 2005 Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168-175
12. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, Maiter D, Pagani MD, Legros JJ, Gianola D, Bex M, Poppe K, Mockel J, Pagani G 2000 Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 143:577-584
13. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ 2008 Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 93:1412-1417
14. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR 2008 Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158:295-303 (Pubitemid 351404992)
15. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S 2005 The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290-6295
16. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ 2009 A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71:549-557
17. Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ 2009 Long term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 71:86-91
18. Pokrajac A, Claridge AG, Shakoor SK, Trainer PJ 2006 The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 154:267-274
19. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA 2005 The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol (Oxf) 62:282-288
20. Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, Puig-Domingo M 2008 A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res 40:422-426 (Pubitemid 351967135)
21. Lundin P, Nyman R, Burman P, Lundberg PO, Muhr C 1992 MRI of pituitary macroadenomas with reference to hormonal activity. Neuroradiology 34:43-51
22. Marro B, Zouaoui A, Sahel M, Crozat N, Gerber S, Sourour N, Sag K, Marsault C 1997 MRI of pituitary adenomas in acromegaly. Neuroradiology 39:394-399
23. Skjødt K, Loft Edal A, Nepper-Rasmussen HJ 1996 Rathke's cleft cyst. Two cases with uncommon MR signals. Acta Radiol 37:596-598
24. Do Amaral LL, Ferreira RM, Ferreira NP, Mendonça RA, Marussi VH, da Cunha JL, Maçaranduba BR, Medeiros JD 2007 Combined pituitary hormone deficiency and PROP-1 mutation in two siblings: a distinct MR imaging pattern of pituitary enlargement. Am J Neuroradiol 28:1369-1370
25. Vieira Neto L, Taboada GF, Gadelha MR 2008 Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly. Arq Bras Endocrinol Metabol 52:1288-1295
26. Vieira Neto L, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer Jr P, de Carvalho DP, Kineman RD, Gadelha MR 2009 Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94:1931-1937